February 27, 2018 / 1:17 PM / in 6 months

BRIEF-Aldeyra Therapeutics Announces Agreement With Johnson & Johnson Innovation To Advance Novel Immune-Modulating Drugs

Feb 27 (Reuters) - Aldeyra Therapeutics Inc:

* ALDEYRA THERAPEUTICS ANNOUNCES AGREEMENT WITH JOHNSON & JOHNSON INNOVATION TO ADVANCE NOVEL IMMUNE-MODULATING DRUGS FOR SYSTEMIC INFLAMMATORY DISEASES

* ALDEYRA THERAPEUTICS INC - ‍ ENTERED INTO A COLLABORATIVE RESEARCH AGREEMENT WITH JANSSEN RESEARCH & DEVELOPMENT​

* ALDEYRA - ‍ AGREEMENT WITH JANSSEN TO ADVANCE DEVELOPMENT OF EXISTING ANALOGS OF REPROXALAP FOR TREATMENT OF SYSTEMIC INFLAMMATORY DISEASES​

* ALDEYRA THERAPEUTICS INC - WILL COLLABORATE WITH JANSSEN ON RESEARCH ACTIVITIES, WHICH WILL BE GOVERNED BY A JOINT SCIENTIFIC REVIEW COMMITTEE​

* ALDEYRA - ‍ FOR A LIMITED PERIOD, SUBJECT TO CONDITIONS, JANSSEN TO RETAIN OPTION TO NEGOTIATE EXCLUSIVE LICENSE PERTAINING TO COMPOUNDS DEVELOPED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below